Incidence of checkpoint inhibitor-related myocarditis in lung cancer patients

Key clinical point: A prospective cohort study found the cumulative incidence of myocarditis among patients treated with immune checkpoint inhibitors (ICI) to be 3%.

Major finding: Three cases (2 definite and 1 possible) of myocarditis were reported over a follow-up of 6 months, with all cases being mild and without major adverse cardiac events. The mean time to onset of myocarditis was 144 ± 3 days.

Study details: The data come from a real-world prospective cohort study involving 99 patients with lung cancer treated with ICI at a French university hospital.

,

Disclosures: No funding information was available. The authors reported no conflicts of interest.

Source: Faubry C et al. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022;9:878211 (Jun 6). Doi: 10.3389/fcvm.2022.878211